CX1739

Last updated
CX1739
CX1739 structure.png
Clinical data
Other namesCX-1739
Legal status
Legal status
Identifiers
  • N-methyl-N-(oxan-4-yl)-2,1,3-benzoxadiazole-5-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C13H15N3O3
Molar mass 261.281 g·mol−1
3D model (JSmol)
  • CN(C1CCOCC1)C(=O)C2=CC3=NON=C3C=C2
  • InChI=1S/C13H15N3O3/c1-16(10-4-6-18-7-5-10)13(17)9-2-3-11-12(8-9)15-19-14-11/h2-3,8,10H,4-7H2,1H3
  • Key:IRYRMRDDVXULFG-UHFFFAOYSA-N

CX1739 is an ampakine drug developed by Cortex Pharmaceuticals. It has similar pharmacological effects and favorable safety profile to older "Type II" ampakines such as CX516 and CX717, but with higher potency and improved bioavailability, unlike "Type I" ampakines such as CX614 which have been found to produce neurotoxicity at high doses. As with related ampakine compounds CX1739 has nootropic effects, and was originally investigated for applications such as treatment of ADHD and dementia, but in the course of testing it was found to be effective as a respiratory stimulant and for facilitating nerve repair, so recent research has focused on potential use for conditions such as sleep apnoea and recovery from spinal cord injury. [1] [2] [3] [4] [5] [6] [7] [8] [9]

See also

References

  1. ↑ Silverman, J.L.; Oliver, C.F.; Karras, M.N.; Gastrell, P.T.; Crawley, J.N. (2013). "AMPAKINE enhancement of social interaction in the BTBR mouse model of autism". Neuropharmacology. 64 (1): 268–282. doi:10.1016/j.neuropharm.2012.07.013. PMC   3445667 . PMID   22801296.
  2. ↑ Ren, Jun; Ding, Xiuqing; Greer, John J. (2015). "Ampakines Enhance Weak Endogenous Respiratory Drive and Alleviate Apnea in Perinatal Rats". American Journal of Respiratory and Critical Care Medicine. 191 (6): 704–710. doi:10.1164/rccm.201410-1898OC. PMID   25594679.
  3. ↑ Radin, Daniel Pierce; Zhong, Sheng; Cerne, Rok; Shoaib, Mohammed; Witkin, Jeffrey M.; Lippa, Arnold (2024). "Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents". Future Pharmacology. 4: 173–187. doi: 10.3390/futurepharmacol4010012 .
  4. ↑ Xiao, Dian; Xie, Fei; Xu, Xin; Zhou, Xinbo (2020). "The Impact and Mechanism of Ampakine CX1739 on Protection Against Respiratory Depression in Rats". Future Medicinal Chemistry. 12 (23): 2093–2104. doi:10.4155/fmc-2020-0256. PMID   33030058.
  5. ↑ Rana, Sabhya; Sunshine, Michael D.; Greer, John J.; Fuller, David D. (2021). "Ampakines Stimulate Diaphragm Activity after Spinal Cord Injury". Journal of Neurotrauma. 38 (24): 3467–3482. doi:10.1089/neu.2021.0301. PMC   8713281 . PMID   34806433.
  6. ↑ Radin, Daniel P.; Zhong, Sheng; Cerne, Rok; Witkin, Jeffrey M.; Lippa, Arnold (2024). "High Impact AMPAkines Induce a Gq-Protein Coupled Endoplasmic Calcium Release in Cortical Neurons: A Possible Mechanism for Explaining the Toxicity of High Impact AMPAkines". Synapse. 78 (5): e22310. doi:10.1002/syn.22310. PMID   39304968.
  7. ↑ Witkin, Jeffrey M.; Radin, Daniel P.; Rana, Sabhya; Fuller, David D.; Fusco, Anna F.; Demers, Julie C.; Pradeep Thakre, Prajwal; Smith, Jodi L.; Lippa, Arnold; Cerne, Rok (2024). "AMPA receptors play an important role in the biological consequences of spinal cord injury: Implications for AMPA receptor modulators for therapeutic benefit". Biochemical Pharmacology. 228. doi:10.1016/j.bcp.2024.116302. PMC  12132907. PMID   38763261.
  8. ↑ Radin, Daniel P.; Cerne, Rok; Witkin, Jeffrey M.; Lippa, Arnold (2025). "Safety, Tolerability, and Pharmacokinetic Profile of the Low-Impact Ampakine CX1739 in Young Healthy Volunteers". Clinical Pharmacology in Drug Development. 14 (1): 50–58. doi:10.1002/cpdd.1475. PMID   39302241.
  9. ↑ Radin, Daniel P.; Lippa, Arnold; Rana, Sabhya; Fuller, David D.; Smith, Jodi L.; Cerne, Rok; Witkin, Jeffrey M. (2025). "Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today". Pharmacology Biochemistry and Behavior. 248. doi:10.1016/j.pbb.2025.173967. PMC  11849398. PMID   39894310.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.